Oramed Pharmaceuticals Inc. (ORMP) Stock Price & Analysis
Oramed Pharmaceuticals Inc. (ORMP) — MoonshotScore 72/100 (Strong band), calculated Nov 18, 2026. Price $3.69 (-5.14%), as of the Nov 19, 2026 trading session; market cap $160M.
Educational signal · not a buy or sell recommendation · How to read this
Oramed Pharmaceuticals Inc. · ORMP · NASDAQ
Oramed Pharmaceuticals Inc. is a biotechnology company focused on developing oral drug delivery systems, particularly for diabetes treatments.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Oramed Pharmaceuticals (ORMP)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, at a dirt-cheap price, though growth is only middling; the market is already moving on it. Business Quality: Solid; Financial Safety: Sound; Valuation: Cheap; Growth Durability: Flat; Momentum: Rising.
- EPS beat 5 of the last 8 reports
- Altman Z 2.81 · Piotroski F 3
- ROE 53.5% · ROA -3.3% · current ratio 6.07
Helping: business quality, an attractive price, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 73 | Strong | |
| 71 | Strong | |
| 71 | Strong | |
| 72 | Strong | |
| 72 | Strong | |
| 72 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $3.69 | |
| Change on the day | -5.14% | |
| Market capitalisation | $160M | — |
| Price / earnings (trailing) | 1.10 | |
| Shares traded on the day | 272.9K |
Price & events
Other perspectives
Council score for Oramed Pharmaceuticals (ORMP): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens reads the current price as undervalued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Oramed Pharmaceuticals (ORMP), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Oramed Pharmaceuticals Inc. (ORMP) is listed on NASDAQ. The market values it at $160M.
What do the latest results show for Oramed Pharmaceuticals (ORMP)?
Short answer · as of
Against analyst estimates the company has EPS beat 5 of the last 8 reports.
What are the financial strengths and risks for Oramed Pharmaceuticals (ORMP)?
Short answer
The MoonshotScore pillars rate business quality, an attractive price, positive momentum as strengths. The distress and quality screens read Altman Z 2.81 · Piotroski F 3. Trailing ratios: ROE 53.5% · ROA -3.3% · current ratio 6.07.
What should you watch next at Oramed Pharmaceuticals (ORMP)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $1.25M · EPS 4.47 · 1 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No quarterly income statement is held for ORMP.
Checked against the records this page reads, on the dates shown above.
How does Oramed Pharmaceuticals compare with its peers?
Short answer
Oramed Pharmaceuticals's score ranks 10th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $1351.12 Nov 19, 2026 | $1.20T | 98 5-pillar Nov 18, 2026 | |
| $13.45 Nov 19, 2026 | $475M | 91 5-pillar Nov 18, 2026 | |
| $9.07 Nov 19, 2026 | $540M | 91 5-pillar Nov 18, 2026 | |
| $3.06 Nov 19, 2026 | $258M | 90 5-pillar Nov 18, 2026 | |
| $41.19 Nov 19, 2026 | $776M | 88 5-pillar Nov 18, 2026 | |
| $38.87 Nov 19, 2026 | $171B | 87 5-pillar Nov 18, 2026 | |
| $46.06 Nov 19, 2026 | $111B | 87 5-pillar Nov 18, 2026 | |
| $11.17 Nov 19, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $15.52 Nov 19, 2026 | $86.9M | 82 5-pillar Nov 18, 2026 | |
| Oramed Pharmaceuticals (ORMP) — this page | $3.69 | $160M | 72 |
| $1.88 Nov 19, 2026 | $178M | 69 5-pillar Nov 18, 2026 | |
| $12.17 Nov 19, 2026 | $861M | 69 5-pillar Nov 18, 2026 | |
| $9.28 Nov 19, 2026 | $545M | 68 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $1.25M
- EPS estimate
- $4.47
Measured against a quoted price of $3.69 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 1, 2026
- Transactions
- 28
- Identified insiders
- 4
- Purchases
- 0
- Sales
- 4
- Other transactions
- 24
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ORMP in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ORMP in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Oramed Pharmaceuticals (ORMP)?
Investor Questions: ORMP Stock
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
What does the MoonshotScore mean for ORMP?
ORMP carries the MoonshotScore stated above — the Strong band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is ORMP a good stock to buy?
Stock Expert AI does not rate ORMP buy, sell or hold. Oramed Pharmaceuticals Inc. carries a MoonshotScore, in the Strong band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ORMP stock price today?
The last price recorded for Oramed Pharmaceuticals Inc. (ORMP), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the key factors to evaluate for ORMP?
Oramed Pharmaceuticals Inc. (ORMP) holds a MoonshotScore in the high range. To weigh it, start with the trailing P/E under Price & valuation on this page. Not financial advice.
How frequently does ORMP data refresh on this page?
ORMP's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ORMP's recent stock price performance?
Oramed Pharmaceuticals Inc. (ORMP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative oral drug delivery technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ORMP overvalued or undervalued right now?
The trailing P/E of Oramed Pharmaceuticals Inc. (ORMP) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of ORMP?
Fractional-share availability for Oramed Pharmaceuticals Inc. (ORMP) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
How can I track ORMP's earnings and financial reports?
Oramed Pharmaceuticals Inc. (ORMP) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for ORMP earnings announcements.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 14 figures on this page — 6 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com